key: cord-0819674-tebwcaf9
authors: Mehta, Puja; Haskard, Dorian O; Laffan, Michael A; Chambers, Rachel C; Hunt, Beverley J
title: Thromboses and COVID-19: reducing inflammation in addition to thromboprophylaxis
date: 2021-01-07
journal: Lancet Rheumatol
DOI: 10.1016/s2665-9913(21)00003-5
sha: ddb229c4333a86070f7d04ecb815b2c30d459b57
doc_id: 819674
cord_uid: tebwcaf9

nan

The COVID-19 pandemic is an unprece dented global health-care emergency, with high mortality in patients who develop COVID-19 pneumonia. These patients have a prothrombotic state with both venous and arterial thrombi occurring despite thromboprophylaxis. Prothrombotic mechanisms are multifactorial, with immune activation leading to an acute phase response, resulting in elevated plasma coagulation factors (particularly fibrinogen). Other features include platelet hyperreactivity, the effects of hypoxia, formation of neutro phil extracellular traps, and comple ment activation. Although very high circulating D-dimer concentrations are observed in patients with COVID-19, there is little evidence of disseminated intravascular coagulation, as thrombocytopenia and hypo fibrinogenaemia are not present and screening clotting times are not prolonged. Many mechanisms driving thromboses in patients with COVID-19 have been suggested, including inflammatory activation of endo thelial cells. We believe that the patho genesis of thrombosis in patients with COVID-19 pneumonia shares similarities with that in patients with Behçet's syndrome.

Behçet's syndrome is a multisystem vasculitis, most commonly characterised by recurrent orogenital ulcers and uveitis. Vascular involvement affects 10-30% of people with Behçet's syndrome, causing mainly superficial or deep venous thrombosis. Vascular wall inflammation, rather than a hypercoagulable state, is the main cause of thromboses in patients with Behçet's syndrome. Hence, treatment guidelines endorse immunosuppression (including steroids and tumour necrosis factor blockade) and discourage the use of anticoagulation, mainly due to the perceived risk of bleeding from covert pulmonary arterial aneurysms, which is not present in patients with COVID-19. 1 Although pulmonary emboli are described in patients with Behçet's syndrome and patients with COVID-19, this term could be misleading, as segmental and subsegmental changes seen on CT pulmonary angiograms might not be caused by emboli but by immunothrombosis or in-situ thrombosis due to local inflammation. There are histological similarities in the two conditions. In patients with Behçet's syndrome, thrombi are tightly adherent to the vessel wall, and some thrombus casts in patients with COVID-19 have been shown to conform to the pulmonary artery vasculature (suggesting in-situ anatomical origin) and to occur without an overt distal embolic source, such as deep venous thrombosis. 2 Therefore, pulmonary inflammation is likely to drive thrombosis in both patients with Behçet's syndrome and patients with COVID-19.

Thromboprophylaxis reduces the risk of venous thromboembolism for unwell, immobile, hospitalised patients by approximately 50%. Pharma co logical thromboprophylaxis improves survival and has become stan dard of care in patients with COVID-19 pneumonia, but throm botic compli ca tions still occur at high rates. We hypothesise that an anti-inflam matory strategy, in addition to thromboprophylaxis, might be beneficial in patients with COVID-19 pneumonia to reduce the burden of immunothrombosis.

The therapeutic potential of targeting inflammation to reduce thromboses was shown by the Canakinumab Antiinflammatory Thrombosis Outcomes Study (CANTOS), 3 a placebo-controlled trial that was published before the COVID-19 pandemic. This trial showed that targeting interleukin-1β significantly reduced the frequency of recurrent thrombotic events (eg, myocardial infarction, stroke, and cardiovascular death), particularly in patients with greater reductions in high-sensitivity C-reactive protein. 3 Although the CANTOS patient population had arterial thromboses only (and are therefore not directly comparable to patients with COVID-19), the results might signal a thera peutic opportunity for patients with COVID-19. A metaanalysis of clinical trials in critically ill patients with COVID-19 showed that systemic cortico steroids were associated with a decreased 28-day all-cause mortality, 4 although the effect of corticosteroids on haemostasis has not yet been reported. A systematic review of glucocorticoid use in patients with inflammatory conditions showed a reduction in the concentration of procoagulant factors (von Willebrand factor and fibrinogen), whereas the plasminogen activator inhibitor-1 (an antifibrinolytic protein) concentration increased . 5 We therefore eagerly await data on the effect of immunomodulatory approaches on thrombotic outcomes in patients with COVID-19.

PM is a Medical Research Council-GlaxoSmithKline (MRC-GSK) Experimental Medicine Initiative to Explore New Therapies (EMINENT) clinical training fellow with project funding, has served on an advisory board for SOBI, outside the submitted work, and receives co-funding by the National Institute for Health Research (NIHR) University College London Hospitals Biomedical Research Centre (UCLH BRC). MAL reports personal fees from Leopharma, Pfizer, Roche-Chugai, SOBI, outside the submitted work. RCC reports grants from the MRC, GSK, and NIHR ULCH BRC, during the conduct of the study. BJH is the medical director of Thrombosis UK and chair of the steering group of World Thrombosis Day, two organisations that are not-for-profit and seek to increase awareness and research into thrombosis. DOH declares no competing interests.

2018 update of the EULAR recommendations for the management of Behçet's syndrome

Megakaryocytes and platelet-fibrin thrombi characterize multi-organ thrombosis at autopsy in COVID-19: a case series

Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial

Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: a meta-analysis

Systematic review on the effect of glucocorticoid use on procoagulant, anti-coagulant and fibrinolytic factors